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In areas where iodized salt is not available, oral iodized oil is often used to correct I de®ciency
despite a lack of consensus on the optimal dose or duration of effect, particularly in children, a
main target group. Annual doses ranging from 400 to 1000 mg have been advocated for school-
age children. Because lower doses of iodized oil have been shown to be effective in treating
I de®ciency in adults, the aim of this study was to evaluate the ef®cacy and safety of a low dose of
oral iodized oil in goitrous I-de®cient children. Goitrous children (n 104, mean age 8×4 years,
range 6±12 years, 47 % female) received 0×4 ml oral iodized poppyseed-oil containing 200 mg I.
Baseline measurements included I in spot urines (UI), serum thyroxine (T4), whole blood thyroid-
stimulating hormone (TSH), and thyroid-gland volume using ultrasound. At 1, 5, 10, 15, 30 and
50 weeks post-intervention, UI, TSH and T4 were measured. At 10, 15, 30 and 50 weeks, thyroid-
gland volume was remeasured. At 30 and 50 weeks the mean percentage change in thyroid
volume from baseline was -35 % and -41 % respectively. The goitre rate fell to 38 % at 30 weeks
and 17 % at 50 weeks. No child showed signs of I-induced hypo- or hyperthyroidism. UI
remained signi®cantly increased above baseline for the entire year (P , 0×001); the median UI at
50 weeks was 97 mg/l, at the World Health Organization cut-off value (100 mg/l) for I-de®ciency
disorders risk. In this group of goitrous children, an oral dose of 200 mg I as Lipiodol (Guerbert,
Roissy CdG Cedex, France) was safe and effective for treating goitre and maintaining normal I
status for at least 1 year.
Iodine: Goitre
In western and central Africa it is estimated that 250 million
people are at risk for I-de®ciency disorders (IDD) and 50
million have goitre (Bailey & Clugston, 1990). A goal of
the World Health Organization is global elimination of
IDD by the year 2000 through iodine supplementation
(World Health Organization, United Nations International
Childrens' Emergency Fund and International Committee
on Control of Iodine De®ciency Disorders, 1994). In areas
where iodized salt is not available, oral iodized oil is often
used to correct I de®ciency despite a lack of consensus on
the optimal dose or duration of effect, particularly in
children, a main target group. Annual doses ranging from
400 to 1000 mg have been advocated for school-age
children (Bautista et al. 1982; Eltom et al. 1985; Benmiloud
et al. 1994; FurneÂe et al. 1995). The manufacturer of
Lipiodol (Guerbet, Roissy CdG Cedex, France), the most
widely used oral iodized oil, recommends 600 mg/year for
6±15-year-old children (Lipiodol Scienti®que: International
Division, 1998). Because of the potential adverse effects of
acute high doses of I in I-de®cient populations (DeLange,
1998), it is important to give the lowest effective dose. Low
doses of iodized oil (118 mg I) have been shown to be
effective in correcting I de®ciency for 1 year in adults
(Tonglet et al. 1992). The aim of this study was therefore
to evaluate the ef®cacy of a low dose of oral iodized oil in
goitrous, I-de®cient children.
Materials and methods
The study was done in two villages in the DananeÂ Health
District, a mountainous region in the western CoÃte d'Ivoire.
In this area of severe I de®ciency, median urinary I
excretion in children is 27 mg/l and 45±55 % of school-
age children are goitrous (Latapie et al. 1981; Zimmermann
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et al. 2000). The study was approved by the Ethical Review
Board of the University Hospital of ZuÈrich, Switzerland, the
National Institute of Public Health and the Ministry of
Research of the CoÃte d'Ivoire. Informed consent was
obtained from the chiefs of the two villages and the families
of the individual children.
All children aged 6±12 years (n 419) in the villages were
screened for goitre and all goitrous children were then
invited to join the intervention study. We enrolled 109
children (mean age 8×4 years, range 6±12 years, 47 %
female) and 104 children completed the study to 1 year.
Baseline measurements before administration of iodized oil
included I in spot urines (UI), serum thyroxine (T4), whole
blood thyroid-stimulating hormone (TSH), and thyroid-
gland volume using ultrasound (Aloka SSD-500, Mure,
Japan). Each child then received 0×4 ml oral iodized poppy-
seed-oil (Lipiodol, Guerbet) containing 200 mg I. At 1, 5,
10, 15, 30 and 50 weeks post-intervention, UI, TSH and T4
were measured. At 10, 15, 30 and 50 weeks, thyroid-gland
volume was remeasured. To avoid interobserver variability,
all ultrasound measurements were performed by a single
investigator (M. Z.). At 10, 15, 30 and 50 weeks height and
weight were remeasured to account for the potential effect
of growth on thyroid volume.
In countries with a high prevalence of child growth
retardation, thyroid volume is considered to be more
directly a function of total body surface area than of age.
Therefore, body surface area was calculated from weight
and height measurements taken with each ultrasound
measurement, and current WHO/International Committee
on Control of Iodine De®ciency Disorders upper normal
limits for thyroid volume in children aged 6±12 years
according to sex, age and body surface area were used to
de®ne the presence or absence of goitre (World Health
Organization/International Committee on Control of Iodine
De®ciency Disorders, 1997).
Portions of blood and urine samples were frozen at -208C
until analysis. UI was measured using a modi®cation of the
Sandell±Kolthoff reaction (Pino et al. 1996). Dried blood
spots on ®lter paper were analysed for whole blood TSH and
serum T4 using immunoassay (Torresani & Scherz, 1986).
Normal reference values are: UI 50±250 mg/l; whole blood
TSH , 3×5 mU/l; serum T4, 65±165 nmol/l. Normally dis-
tributed data were expressed as means and standard devia-
tions and were compared by Student's t test. Variables not
normally distributed (UI, TSH) were expressed as medians
(95 % CI) and were compared by Mann-Whitney tests.
Results and Discussion
At 30 and 50 weeks the mean percentage changes in thyroid
volume from baseline were -35 % and -41 % respectively
(see Table 1). The goitre rate fell to 38 % at 30 weeks and
17 % at 50 weeks. UI remained signi®cantly increased
above baseline for the entire year (P , 0×001); the median
UI at 50 weeks was 97 mg/l, at the WHO cut-off value
(100 mg/l) for IDD risk. Baseline and follow-up median
TSH and mean serum T4 were within the normal range in
both groups. Although there was a small transient increase
in mean TSH at 1 week after I, values at 5, 10, and 15
weeks were reduced signi®cantly (P , 0×05) compared
with baseline. No child showed signs of I-induced hypo-
or hyperthyroidism.
Previous studies of oral iodized oil in children have
generally given doses .2-fold higher than the 200 mg I
used in this study. Based on studies in Bolivian children,
Bautista et al. (1982) recommended annual doses of 700±
1000 mg oral I. In a study by Benmiloud et al. (1994)
comparing different doses of oral iodized oil in I-
de®cient Algerian children aged 6±11 years, oral I doses
of 480 and 960 mg were effective at maintaining adequate
UI excretion (.50 mg/l) for 1 year. An oral dose of 240 mg I
maintained urinary excretion .50 mg/l for at least 6 months,
but there was no signi®cant decrease in mean thyroid
volume after treatment (Benmiloud et al. 1994). In I-
de®cient schoolchildren in the Sudan, an oral dose of
400 mg I signi®cantly decreased goitre prevalence and
maintained adequate UI excretion for 1 year (Eltom et al.
1985). In I-de®cient 8±10-year-old Malawian children, a
single 490 mg dose of I as oral iodized oil (Lipiodol,
Guerbet) maintained adequate UI excretion (.50 mg/l)
for only 14 weeks, whereas an oral dose of 675 mg I as
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Table 1. Changes in thyroid size, goitre prevalence, urinary iodine, thyroid-stimulating hormone (TSH) and thyroxine (T4) in goitrous children after
receiving 200 mg oral iodine




volume (ml) baseline (%)² Prevalence Urinary iodine (mg/l) TSH (mU/l) T4 (nmol/l)
Time after of goitre
oral iodine Mean SD Mean SD (%) Median 95 % CI Median 95 % CI Mean SD
Baseline 8×3 2×0 100 28 29, 46 1×0 0×9, 1×4 121 26
1 week 1100*** 1192, 2015 1×6 1×4, 2×2 123 25
5 weeks 324*** 302, 412 0×6* 0×5, 0×7 107 21
10 weeks 6×5*** 2×1 -21 18 64 171*** 169, 252 0×7* 0×6, 0×9 105 25
15 weeks 5×6*** 1×8 -31 16 47 178*** 167, 244 0×6* 0×5, 0×9 109 20
30 weeks 5×4*** 1×7 -35 15 38 135*** 122, 163 0×8 0×7, 1×1 133 30
50 weeks 4×9*** 1×6 -41 13 17 96*** 87, 118 0×8 0×7, 1×2 132 34
Mean or median values were signi®cantly different from values at baseline, *P, 0×05, ***P, 0×001.
² To reduce the effects of variability among individuals, percentage change in thyroid volume from baseline was calculated for each child before deriving means.
Thyroid volume was not measured at 1 and 5 weeks.
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triacylglycerol esters of iodized fatty acids (Oriodol, Guer-
bet) maintained adequate UI excretion for 1 year (FurneÁe
et al. 1995). Varying conditions in these studies (age and
number of subjects, severity of I de®ciency, location, ultra-
sound v. palpation for goitre grading) make it dif®cult to
compare results.
Because of the potential adverse effects of acute doses of
I in I-de®cient populations, it is important to give the lowest
effective dose. The most common serious complication
observed in areas of endemic goitre during introduction of
I is a transient increase in I-induced hyperthyroidism, which
affects mainly older adults and those with nodular goitres
(DeLange, 1998; Stanbury et al, 1998). In previous studies
in I-de®cient children using higher doses of oral iodized oil,
side effects have been reported in up to 4 % of children
(Eltom et al. 1985; Benmiloud et al. 1994). In the present
study, no child showed signs of I-induced hypo- or
hyperthyroidism. This difference may be due to the use of
a lower dose of I in a study population of children with
small-to-moderately-sized, non-nodular goitres.
In this area of the CoÃte d'Ivoire, nearly half of school-age
children suffer from goitre. Severe I de®ciency is com-
pounded by high intakes of cassava and elevated urinary
thiocyanate (SCN) excretion; median UI : SCN ratio in urine
is , 2 mg/mg, indicating increased risk for exacerbation of
goitre by thiocyanate (Bourdoux et al. 1978). Other nutri-
tional factors which may impair thyroid metabolism are
common: the children are severely Se de®cient (mean serum
Se ,15 mg/l) and 27 % suffer from Fe-de®ciency anemia
(Zimmermann et al. 2000). Despite these unfavorable con-
ditions, a low oral dose of 200 mg I was safe and effective
for treating goitre and maintaining normal I status for at
least 1 year.
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